A Study to Evaluate the Safety and Effectiveness of TRIGEN™ INTERTAN™ (10S Models)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-23

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a post-market study to evaluate the revision rate of femoral fractures, treated with INTERTAN 10S Nails at one-year post-operation. The study will enroll Approximately 180 subjects with femoral fractures, Approximately 7 sites are involved. The study duration will be Approximately 36 months (6 months start-up, 1 year enrollment, 1 year follow-up, 6 months closeout/study report).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trigen InterTAN vs Sliding Hip Screw RCT

NCT03065101

Hip Fractures

TERMINATED NA

Comparing Weight Bearing After Intramedullary Fixation Devices for the Proximal Femur Fracture

NCT01509859

Closed Comminuted Oblique Intertrochanteric Fracture of Neck of Right Femur Closed Comminuted Oblique Intertrochanteric Fracture of Neck of Left Femur

UNKNOWN PHASE4

Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures

NCT01282294

Tibia Fractures

COMPLETED

Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals

NCT00593333

Femur Fracture

COMPLETED NA

Efficacy Study of Surgical Technique in Intramedullary Tibia Nailing, Using Trigen META Tibia Nails

NCT01358292

Tibial Fractures

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

The INTERTAN nail was designed to improve upon existing intramedullary nail systems. INTERTAN nails utilize two interlocking screws, thereby improving controlled intertochanteric fracture compression and post-surgical stability.

Purpose:

Evaluate the revision rate of femoral fractures, treated with INTERTAN 10S Nails at one-year post-operation

Objectives:

* Primary Objective: To evaluate the revision rate for any reason of femoral fractures, treated with INTERTAN 10S Nails at one year post-operation
* Secondary Objective: To generate safety and effectiveness evidence for INTERTAN 10S Nails via the collection of functional outcomes, quality of life, and safety data

Research participants / locations:

The study will enroll Approximately 180 subjects with femoral fractures, Approximately 7 sites in China are involved.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femoral Fractures Hip Fractures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRIGEN™ INTERTAN™

Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail

TRIGEN™ INTERTAN™

Intervention Type DEVICE

Femoral fracture treated with INTERTAN 10S Nail

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TRIGEN™ INTERTAN™

Femoral fracture treated with INTERTAN 10S Nail

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who sign the informed consent form (ICF) voluntarily.
* Subjects who have a femoral fracture and are scheduled for repair using an INTERTAN 10S Nail.
* Male or female subjects aged 18 years or older, with mature bone development at time of implantation.
* Subjects who agree to follow all study visits and procedures.

Exclusion Criteria

* Subjects with known hypersensitivity to the device or implant materials.
* Subjects in which use of the device would cross open epiphyseal plate(s).
* Subjects with complex intertrochanteric and femoral neck fractures.
* Subjects with an existing condition that predisposes them to a poor outcome, such as blood supply limitations, insufficient bone quality or quantity, obliterated medullary canal, previous infections or other conditions which tend to retard healing.
* Subjects not suitable for operation due to obvious local or systemic infection.
* Subjects who are unable to tolerate anesthesia and surgery due to cardiopulmonary failure or other serious diseases.
* Subjects with a congenital or acquired bony deformity.
* Subjects with Body Mass Index (BMI) of ≥ 35.
* Subjects with hypovolemia, hypothermia, or coagulopathy.
* Subject is immunosuppressed, has an autoimmune disorder or an immunosuppressive disorder. For examples, subjects are on immunosuppressive therapy (cortisol at large dose, cytotoxic drugs, antilymphocytic serum or irradiation at large doses) or has acquired immunodeficiency syndrome (AIDS).
* Subjects with any existing hardware that would preclude the use of the nail.
* Subjects with mental or emotional conditions or any other clinical conditions that, in the opinion of the Investigator, would preclude cooperation and compliance with the rehabilitation regimen.
* Subjects with medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
* Subject is a woman who is pregnant or lactating, or intends to become pregnant during the course of the study follow-up.
* Subjects who have participated in any other clinical trial within 3 months of Screening.
* Subjects who have participated previously in this clinical study and were withdrawn for any reason.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No